```
NSPEC   IS R      AT  23
NSPEC   IS C      AT  24
NSPEC   IS C      AT  25
NSPEC   IS C      AT  26
NSPEC   IS C      AT  27
NSPEC   IS C      AT  28
NSPEC   IS C      AT  29
NSPEC   IS C      AT  30
NSPEC   IS C      AT  31
NSPEC   IS C      AT  32
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  24 25 27 29 31 32 33 34 35 36 37 38 39 40
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  40

STEREO ATTRIBUTES: NONE
L8            93 SEA FILE=REGISTRY SSS FUL L1
L10            7 SEA FILE=CAPLUS ABB=ON  PLU=ON  L8


=> d ibib abs hitstr l10 tot

L10  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:767285  CAPLUS
DOCUMENT NUMBER:          141:410789
TITLE:                    Benzothiophene and naphthalene derived constrained
                          SERMs
AUTHOR(S):                Wallace, Owen B.; Bryant, Henry U.; Shetler, Pamela
                          K.; Adrian, Mary D.; Geiser, Andrew G.
CORPORATE SOURCE:         Lilly Research Laboratories, Eli Lilly and Company,
                          Lilly Corporate Center, Indianapolis, IN, 46285, USA
SOURCE:                   Bioorganic & Medicinal Chemistry Letters (2004),
                          14(20), 5103-5106
                          CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER:                Elsevier B.V.
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
OTHER SOURCE(S):          CASREACT 141:410789
AB   For selective estrogen receptor modulators (SERMs), the orientation of the
     basic side chain relative to the SERM core has a significant impact on
     function.  The synthesis and biol. evaluation of two series of SERMs are
     disclosed, where the ligand side chain is constrained to adopt a defined
     orientation.  Compds. where the side chain is forced into the plane of the
     SERM core have a different profile compared to those compds. where the
     side chain is pseudo-orthogonal, particularly with regard to antagonism of
     estradiol action on an Ishikawa uterine cell line.
IT   676456-49-8P 676456-50-1P
     RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
     (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
        (preparation of piperazinoethoxyphenylbenzonaphthothiophenes and
        -benzanthracenes as selective estrogen receptor modulators)
RN   676456-49-8  CAPLUS
CN   Benz[a]anthracene-3,9-diol, 7,12-dihydro-12-[4-[2-(1-
     piperidinyl)ethoxy]phenyl]-, (12S)- (9CI)  (CA INDEX NAME)

Absolute stereochemistry.
```



RN 676456-50-1 CAPLUS
CN Benz[a]anthracene-3,9-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, (12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **676456-27-2P 676456-30-7P 676456-33-0P**
676456-36-3P 676456-43-2P 676456-46-5P
676456-51-2P 676456-53-4P 791837-74-6P
791837-75-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of piperazinoethoxyphenylbenzonaphthothiophenes and -benzanthracenes as selective estrogen receptor modulators)

RN 676456-27-2 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene-3-ol, 6,11-dihydro-11-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-30-7 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene-3,8-diol, 6,11-dihydro-11-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-33-0 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene-3,10-diol, 6,11-dihydro-11-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-36-3 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene-3,9-diol, 6,11-dihydro-11-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-43-2 CAPLUS
CN Benz[a]anthracene-3,10-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-46-5 CAPLUS
CN Benz[a]anthracene-3,9-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-51-2 CAPLUS
CN Benz[a]anthracene-3,11-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-53-4 CAPLUS
CN Benz[a]anthracene-3,8-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 791837-74-6 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene-3,9-diol, 11-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 791837-75-7 CAPLUS
CN Benz[a]anthracene-3,10-diol, 12-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:292023 CAPLUS
DOCUMENT NUMBER: 140:303419
TITLE: Preparation of dihydro-dibenzo(a)anthracenes as selective estrogen receptor modulators
INVENTOR(S): Wallace, Owen Brendan
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029047	A1	20040408	WO 2003-US26304	20030922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497627	AA	20040408	CA 2003-2497627	20030922
AU 2003265581	A1	20040419	AU 2003-265581	20030922
EP 1546139	A1	20050629	EP 2003-798700	20030922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014594	A	20050809	BR 2003-14594	20030922
JP 2006508066	T2	20060309	JP 2004-539841	20030922
PRIORITY APPLN. INFO.:			US 2002-413609P P	20020925
			WO 2003-US26304 W	20030922

OTHER SOURCE(S): MARPAT 140:303419
GI



I



II

AB Dihydro-dibenzo(a)anthracenes of formula I [R1 = H, OH, alkoxy, benzoyloxy, acyloxy, OSO2alkyl, etc.; R, R2, R3 = H, OH, alkoxy, benzoyloxy, acyloxy, OSO2alkyl, halo; R4 = 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n = 2-3; X = S, CH=CH; Y = O, S, NH, NMe, CH2] are prepared for pharmaceutical compns., optionally in combination with estrogen and progestin, for inhibiting a disease associated with estrogen deprivation or a disease associated with an aberrant physiol. response to endogenous estrogen. Thus, II.TFA was prepared from (2,6-dimethoxynaphthalen-1-yl)-[4-(2-piperidin-1-ylethoxy)phenyl]methanone and 3-methoxybenzylzinc chloride. II had IC50 of 2 nM against MCF-7 breast adenocarcinoma cells.

IT **676456-27-2P 676456-28-3P 676456-30-7P**
676456-31-8P 676456-33-0P 676456-34-1P
676456-36-3P 676456-37-4P 676456-38-5P
676456-39-6P 676456-41-0P 676456-43-2P
676456-44-3P 676456-46-5P 676456-47-6P
676456-49-8P 676456-50-1P 676456-51-2P
676456-52-3P 676456-53-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydro-dibenzoanthracenes as selective estrogen receptor modulators)

RN 676456-27-2 CAPLUS

CN Benzo[b]naphtho[2,3-d]thiophene-3-ol, 6,11-dihydro-11-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-28-3 CAPLUS

CN Benzo[b]naphtho[2,3-d]thiophene-3-ol, 6,11-dihydro-11-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676456-27-2

CMF C29 H29 N O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 676456-30-7 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene-3,8-diol, 6,11-dihydro-11-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-31-8 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene-3,8-diol, 6,11-dihydro-11-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676456-30-7
CMF C29 H29 N O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 676456-33-0 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene-3,10-diol, 6,11-dihydro-11-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-34-1 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene-3,10-diol, 6,11-dihydro-11-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676456-33-0
CMF C29 H29 N O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 676456-36-3 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene-3,9-diol, 6,11-dihydro-11-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-37-4 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene-3,9-diol, 6,11-dihydro-11-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676456-36-3
CMF C29 H29 N O3 S



CM 2

CRN 76-05-1



RN 676456-41-0 CAPLUS
CN Benz[a]anthracen-3-ol, 10-fluoro-7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, (12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676456-43-2 CAPLUS
CN Benz[a]anthracene-3,10-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

CMF C2 H F3 O2



RN 676456-38-5 CAPLUS
CN Benz[a]anthracen-3-ol, 10-fluoro-7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-39-6 CAPLUS
CN Benz[a]anthracen-3-ol, 10-fluoro-7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, (12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676456-46-5 CAPLUS
CN Benz[a]anthracene-3,9-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-47-6 CAPLUS
CN Benz[a]anthracene-3,9-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676456-46-5
CMF C31 H31 N O3



RN 676456-44-3 CAPLUS
CN Benz[a]anthracene-3,10-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676456-43-2
CMF C31 H31 N O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 676456-49-8 CAPLUS
CN Benz[a]anthracene-3,9-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, (12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676456-50-1 CAPLUS
CN Benz[a]anthracene-3,9-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, (12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676456-51-2 CAPLUS
CN Benz[a]anthracene-3,11-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676456-52-3 CAPLUS
CN Benz[a]anthracene-3,11-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676456-51-2
CMF C31 H31 N O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 676456-53-4 CAPLUS
CN Benz[a]anthracene-3,8-diol, 7,12-dihydro-12-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:607330 CAPLUS
DOCUMENT NUMBER: 133:193067
TITLE: Preparation of 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes for treating insulin resistance and hyperglycemia
INVENTOR(S): Wrobel, Jay E.; Dietrich, Arlene J.; Li, Zenan
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: U.S., 67 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6110962	A	20000829	US 1999-307840		19990510
PRIORITY APPLN. INFO.:			US 1998-98554P	P	19980512
OTHER SOURCE(S):	MARPAT 133:193067				

GI



I

AB The title compds. [I; A = H, halo, OH; B, D = H, halo, CN, etc.; E = S, SO, SO2, O; X = H, halo, alkyl, etc.; Y, Z = H, OR2; R2 = H, alkyl, aralkyl, CH2CO2R3; R3 = H, alkyl; C = H, halo, OR4 ; R4 = H, alkyl, CH(R5)W, etc.; R5 = H, alkyl, aralkyl, etc.; W = CONH2, CONHOH, CN, etc.; with the proviso that at least one of A-D is not H atom] and their pharmaceutically acceptable salts, which are useful in treating insulin resistance and hyperglycemia, were prepared E.g., a multi-step synthesis of I [A, B, D = H; C = OH; E = S; X, Y, Z = H] which showed -34.19% change from control in test for PTPase inhibition at 50 μM, was given.

IT **245359-81-3P 250350-47-1P 250350-48-2P**
250350-50-6P 250350-83-5P 250350-92-6P
250350-97-1P 250351-01-0P 250351-10-1P
250351-24-7P 250351-26-9P 250351-40-7P
289628-82-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes for treating insulin resistance and hyperglycemia)

RN 245359-81-3 CAPLUS

CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250350-47-1 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-48-2 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250350-50-6 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-methoxybenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-83-5 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-1,3-dihydro-1,3-dioxo-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-92-6 CAPLUS
CN 2-Naphthalenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, 1,1-dimethylethyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-97-1 CAPLUS
CN Phosphonic acid, [1-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-3-phenylpropyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 250351-01-0 CAPLUS
CN Benzenepropanamide, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-10-1 CAPLUS
CN Benzenepropanol, β-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-24-7 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-hydroxybenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-26-9 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(phenylmethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-40-7 CAPLUS
CN Phenol, 3-bromo-5-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 289628-82-6 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-4-fluoro-, 1,1-dimethylethyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **245359-83-5P 250350-49-3P 250350-52-8P**
250350-53-9P 250350-54-0P 250350-55-1P
250350-57-3P 250350-58-4P 250350-60-8P
250350-62-0P 250350-63-1P 250350-64-2P
250350-65-3P 250350-66-4P 250350-68-6P
250350-69-7P 250350-71-1P 250350-72-2P
250350-74-4P 250350-75-5P 250350-76-6P
250350-77-7P 250350-79-9P 250350-80-2P
250350-84-6P 250350-85-7P 250350-86-8P
250350-87-9P 250350-90-4P 250350-93-7P
250350-94-8P 250350-99-3P 250351-02-1P
250351-06-5P 250351-07-6P 250351-09-8P
250351-12-3P 250351-28-1P 250351-30-5P
250351-32-7P 250351-36-1P 250351-37-2P
250351-43-0P 250351-91-8P 250636-53-4P
289628-80-4P 289628-81-5P 289628-83-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes for treating insulin resistance and hyperglycemia)

RN 245359-83-5 CAPLUS

CN 2H-Isoindole-2-butanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-1,3-dihydro-1,3-dioxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-49-3 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250350-52-8 CAPLUS
CN Benzenepropanoic acid, α-[4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250350-53-9 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-cyanobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-54-0 CAPLUS
CN Benzenepropanoic acid, α-[4-(6-cyanobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250350-55-1 CAPLUS
CN Benzenepropanoic acid, α-(4-benzo[b]naphtho[2,3-d]thien-11-ylphenoxy)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250350-57-3 CAPLUS
CN Benzenepropanoic acid, α-[4-[3-(carboxymethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-58-4 CAPLUS
CN 1H-Imidazole-4-propanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-60-8 CAPLUS
CN 1H-Indole-3-propanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 250350-62-0 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-1,3-dihydro-1-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-63-1 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(trifluoromethyl)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250350-64-2 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-methoxybenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-65-3 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-chlorobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250350-66-4 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(phenylthio)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-68-6 CAPLUS
CN Benzenepropanoic acid, α-[4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)-2,6-dichlorophenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-69-7 CAPLUS
CN Benzenepropanoic acid, α-(4-benzo[b]naphtho[2,3-d]thien-11-yl-2,6-diiodophenoxy)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-71-1 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-[[2-(dimethylamino)ethyl]thio]benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-72-2 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(4-pyridinylthio)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-74-4 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-iodobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250350-75-5 CAPLUS
CN 3-Pyridinepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



RN 250350-76-6 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dimethyl-4-(6-methylbenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-77-7 CAPLUS
CN Benzenepropanoic acid, α-[4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)-2,6-bis(1-methylethyl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-79-9 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-methylbenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250350-80-2 CAPLUS
CN Benzeneacetic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-84-6 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-(4-benzo[b]naphtho[2,3-d]thien-11-yl-2,6-dibromophenoxy)-1,3-dihydro-1,3-dioxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-85-7 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-(4-benzo[b]naphtho[2,3-d]thien-11-ylphenoxy)-1,3-dihydro-1,3-dioxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-86-8 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-[4-[3-(carboxymethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-1,3-dihydro-1,3-dioxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-87-9 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-[4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-1,3-dihydro-1,3-dioxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-90-4 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-4-fluoro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 250350-93-7 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-4-fluoro- (9CI) (CA INDEX NAME)



RN 250350-94-8 CAPLUS
CN 2-Naphthalenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 250350-99-3 CAPLUS
CN Phosphonic acid, [1-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-3-phenylpropyl]- (9CI) (CA INDEX NAME)



RN 250351-02-1 CAPLUS
CN Benzenepropanamide, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-N-hydroxy-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-06-5 CAPLUS
CN Benzenepropanenitrile, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-07-6 CAPLUS
CN 1H-Tetrazole, 5-[[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 250351-09-8 CAPLUS
CN 1H-Tetrazole, 5-[(1R)-1-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-12-3 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene, 6-bromo-11-[3,5-dibromo-4-[(R)-1-(bromomethyl)-2-phenylethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-28-1 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(2-methoxy-2-oxoethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 250351-30-5 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(phenylmethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250351-32-7 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(carboxymethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250351-36-1 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromo-5,5-dioxidobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250351-37-2 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromo-5,5-dioxidobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250351-43-0 CAPLUS
CN Benzenepropanoic acid, α-[2-bromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)-6-methoxyphenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-91-8 CAPLUS
CN 3-Pyridinepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 250636-53-4 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, sodium salt, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 289628-80-4 CAPLUS
CN Benzenebutanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 289628-81-5 CAPLUS
CN Benzenebutanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 289628-83-7 CAPLUS
CN Benzenepropanamide, N-(2-cyanoethyl)-α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **250351-88-3 250351-89-4 250351-90-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes for treating insulin resistance and hyperglycemia)
RN 250351-88-3 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-(4-benzo[b]naphtho[2,3-d]thien-11-ylphenoxy)-1,3-dihydro-1,3-dioxo-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-89-4 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-[4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-1,3-dihydro-1,3-dioxo-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-90-7 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(carboxymethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, monomethyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **250351-75-8P 289628-85-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes for treating insulin resistance and hyperglycemia)

RN 250351-75-8 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene, 6-bromo-11-[3-bromo-5-methoxy-4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 289628-85-9 CAPLUS
CN Benzenebutanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, ethyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:496102 CAPLUS
DOCUMENT NUMBER: 133:266758
TITLE: Synthesis and PTP1B inhibition of novel 4-aryl-1-oxa-9-thiacyclopenta[b]fluorenes
AUTHOR(S): Wrobel, J.; Li, Z.; Sredy, J.; Sawicki, D. R.; Seestaller, L.; Sullivan, D.
CORPORATE SOURCE: Wyeth-Ayerst Research, Inc., Princeton, NJ, 08543-8000, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000),

10(14), 1535-1538
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Novel 4-aryl-1-oxa-9-thiacyclopenta[b]fluorenes were designed, synthesized, and evaluated as inhibitors of the protein tyrosine phosphatase, PTP1B. The target compds. thus prepared were (αR)-α-(4-benzo[b]naphtho[2,3-d]thien-11-yl-2,6-diiodophenoxy)benzenepropanoic acid, (2R)-2-[4-(2,3-dimethyl[1]benzothieno[3,2-f]benzofuran-4-yl)-2,6-diiodophenoxy]propanoic acid, and (αR)-α-[4-(2,3-dimethyl[1]benzothieno[3,2-f]benzofuran-4-yl)-2,6-diiodophenoxy]benzenepropanoic acid (I). These compds. showed nanomolar potency against PTP1B (TRDI(P)YETD(P)Y(P)YRK as substrate). I also lowered insulin in the diabetic ob/ob mouse at a dose of 10 mg/kg/day, po.

IT **250350-69-7P**, (αR)-α-(4-Benzo[b]naphtho[2,3-d]thien-11-yl-2,6-diiodophenoxy)benzenepropanoic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and tyrosine phosphatase-inhibiting (antidiabetic) activity of (aryl)oxathiacyclopenta[b]fluorenes)

RN 250350-69-7 CAPLUS

CN Benzenepropanoic acid, α-(4-benzo[b]naphtho[2,3-d]thien-11-yl-2,6-diiodophenoxy)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:304861 CAPLUS
DOCUMENT NUMBER: 133:83859
TITLE: PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes
AUTHOR(S): Li, Jie Jack; Visnick, Mike
CORPORATE SOURCE: Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, USA

SOURCE: Chemtracts (2000), 13(4), 259-264
CODEN: CHEMFW; ISSN: 1431-9268
PUBLISHER: Springer-Verlag New York Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB The title research of J. Wrobel et al. (1999) is reviewed with commentary and 3 refs.

IT **245359-81-3P 280563-81-7P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(antihyperglycemic and PTP1B-inhibiting SAR in the ob/ob mouse model of novel arylbenzonaphthofurans and arylbenzonaphthothiophenes)

RN 245359-81-3 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 280563-81-7 CAPLUS
CN 2H-Isoindole-2-propanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-1,3-dihydro-1,3-dioxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:736689 CAPLUS
DOCUMENT NUMBER: 131:351227
TITLE: Preparation of 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia
INVENTOR(S): Wrobel, Jay Edward; Dietrich, Arlene Joan; Li, Zenan
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: PCT Int. Appl., 209 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9958521	A1	19991118	WO 1999-US10185		19990510
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2330623	AA	19991118	CA 1999-2330623		19990510
AU 9939791	A1	19991129	AU 1999-39791		19990510
EP 1077970	A1	20010228	EP 1999-922897		19990510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO					
JP 2002514638	T2	20020521	JP 2000-548325		19990510
PRIORITY APPLN. INFO.:			US 1998-76592	A	19980512
			WO 1999-US10185	W	19990510

OTHER SOURCE(S): MARPAT 131:351227
GI



I

AB The title compds. [I; A = H, halo, OH; B, D = H, halo, CN, etc.; E = S, SO, SO2, O; X = H, halo, alkyl, etc.; Y, Z = H, OR2; R2 = H, alkyl, aralkyl, etc.; C = H, halo, OR4; R4 = H, alkyl, 5-thiazolidine-2,4-dione, etc.] and their pharmaceutically acceptable salts, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia, were prepared Thus, treatment of 4-benzo[b]naphtho[2,3-d]thiophen-11-ylphenol and KOAc in AcOH with a solution of Br2 in glacial AcOH afforded I [E = S; Y = Z = H; X = Br; A = H; B = D = Br; C = OH] which showed IC50 of 0.384 μM against human recombinant PTP1B.

IT **245359-81-3P 250350-47-1P 250350-48-2P**
250350-50-6P 250350-83-5P 250350-92-6P
250350-97-1P 250351-01-0P 250351-10-1P
250351-24-7P 250351-26-9P 250351-36-1P
250351-40-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia)

RN 245359-81-3 CAPLUS

CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250350-47-1 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-48-2 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250350-50-6 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-methoxybenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-83-5 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-1,3-dihydro-1,3-dioxo-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-92-6 CAPLUS
CN 2-Naphthalenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, 1,1-dimethylethyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-97-1 CAPLUS
CN Phosphonic acid, [1-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-3-phenylpropyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 250351-01-0 CAPLUS
CN Benzenepropanamide, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-10-1 CAPLUS
CN Benzenepropanol, β-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-24-7 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-hydroxybenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-26-9 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(phenylmethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-36-1 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromo-5,5-dioxidobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250351-40-7 CAPLUS
CN Phenol, 3-bromo-5-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)



IT **245359-83-5P 250350-49-3P 250350-51-7P**
250350-52-8P 250350-53-9P 250350-54-0P
250350-55-1P 250350-56-2P 250350-57-3P
250350-58-4P 250350-60-8P 250350-62-0P
250350-63-1P 250350-64-2P 250350-65-3P
250350-66-4P 250350-68-6P 250350-69-7P
250350-71-1P 250350-72-2P 250350-74-4P
250350-75-5P 250350-76-6P 250350-77-7P
250350-79-9P 250350-80-2P 250350-84-6P
250350-85-7P 250350-86-8P 250350-87-9P
250350-90-4P 250350-93-7P 250350-94-8P
250350-99-3P 250351-02-1P 250351-03-2P
250351-06-5P 250351-07-6P 250351-09-8P
250351-12-3P 250351-28-1P 250351-30-5P
250351-32-7P 250351-37-2P 250351-43-0P
250351-91-8P 250636-53-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia)

RN 245359-83-5 CAPLUS

CN 2H-Isoindole-2-butanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-1,3-dihydro-1,3-dioxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-49-3 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250350-51-7 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-β-methyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-52-8 CAPLUS
CN Benzenepropanoic acid, α-[4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250350-53-9 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-cyanobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-54-0 CAPLUS
CN Benzenepropanoic acid, α-[4-(6-cyanobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250350-55-1 CAPLUS
CN Benzenepropanoic acid, α-(4-benzo[b]naphtho[2,3-d]thien-11-ylphenoxy)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 250350-56-2 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-β-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-57-3 CAPLUS
CN Benzenepropanoic acid, α-[4-[3-(carboxymethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-58-4 CAPLUS
CN 1H-Imidazole-4-propanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-60-8 CAPLUS
CN 1H-Indole-3-propanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 250350-62-0 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-1,3-dihydro-1-oxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-63-1 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(trifluoromethyl)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250350-64-2 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-methoxybenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-65-3 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-chlorobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250350-66-4 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(phenylthio)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-68-6 CAPLUS
CN Benzenepropanoic acid, α-[4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)-2,6-dichlorophenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-69-7 CAPLUS
CN Benzenepropanoic acid, α-(4-benzo[b]naphtho[2,3-d]thien-11-yl-2,6-diiodophenoxy)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-71-1 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-[[2-(dimethylamino)ethyl]thio]benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-72-2 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(4-pyridinylthio)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-74-4 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-iodobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250350-75-5 CAPLUS
CN 3-Pyridinepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)



RN 250350-76-6 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dimethyl-4-(6-methylbenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-77-7 CAPLUS
CN Benzenepropanoic acid, α-[4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)-2,6-bis(1-methylethyl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-79-9 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-methylbenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250350-80-2 CAPLUS
CN Benzeneacetic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-84-6 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-(4-benzo[b]naphtho[2,3-d]thien-11-yl-2,6-dibromophenoxy)-1,3-dihydro-1,3-dioxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-85-7 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-(4-benzo[b]naphtho[2,3-d]thien-11-ylphenoxy)-1,3-dihydro-1,3-dioxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-86-8 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-[4-[3-(carboxymethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-1,3-dihydro-1,3-dioxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-87-9 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-[4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-1,3-dihydro-1,3-dioxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250350-90-4 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-4-fluoro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 250350-93-7 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-4-fluoro- (9CI) (CA INDEX NAME)



RN 250350-94-8 CAPLUS
CN 2-Naphthalenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 250350-99-3 CAPLUS
CN Phosphonic acid, [1-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-3-phenylpropyl]- (9CI) (CA INDEX NAME)



RN 250351-02-1 CAPLUS
CN Benzenepropanamide, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-N-hydroxy-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-03-2 CAPLUS
CN Benzenepropanamide, N-(1-cyanoethyl)-α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-06-5 CAPLUS
CN Benzenepropanenitrile, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-07-6 CAPLUS
CN 1H-Tetrazole, 5-[[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 250351-09-8 CAPLUS
CN 1H-Tetrazole, 5-[(1R)-1-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-12-3 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene, 6-bromo-11-[3,5-dibromo-4-[(R)-1-(bromomethyl)-2-phenylethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-28-1 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(2-methoxy-2-oxoethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 250351-30-5 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(phenylmethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250351-32-7 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(carboxymethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250351-37-2 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromo-5,5-dioxidobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 250351-43-0 CAPLUS
CN Benzenepropanoic acid, α-[2-bromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)-6-methoxyphenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-91-8 CAPLUS
CN 3-Pyridinepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 250636-53-4 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, sodium salt, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **250351-88-3 250351-89-4 250351-90-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia)
RN 250351-88-3 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-(4-benzo[b]naphtho[2,3-d]thien-11-ylphenoxy)-1,3-dihydro-1,3-dioxo-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-89-4 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-[4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-1,3-dihydro-1,3-dioxo-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 250351-90-7 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-[6-(carboxymethoxy)benzo[b]naphtho[2,3-d]thien-11-yl]phenoxy]-, monomethyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **250351-75-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia)
RN 250351-75-8 CAPLUS
CN Benzo[b]naphtho[2,3-d]thiophene, 6-bromo-11-[3-bromo-5-methoxy-4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:499895 CAPLUS
DOCUMENT NUMBER: 131:266554
TITLE: PTP1B Inhibition and Antihyperglycemic Activity in the ob/ob Mouse Model of Novel 11-Arylbenzo[b]naphtho[2,3-d]furans and 11-Arylbenzo[b]naphtho[2,3-d]thiophenes
AUTHOR(S): Wrobel, Jay; Sredy, Janet; Moxham, Christopher; Dietrich, Arlene; Li, Zenan; Sawicki, Diane R.;

Seestaller, Laura; Wu, Li; Katz, Alan; Sullivan, Donald; Tio, Cesario; Zhang, Zhong-Yin
CORPORATE SOURCE: Wyeth-Ayerst Research Inc., Princeton, NJ, 08543-8000, USA
SOURCE: Journal of Medicinal Chemistry (1999), 42(17), 3199-3202
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB 6 Title compds. were prepared and 2 shown to be potent, selective PTPase inhibitors that function as oral antidiabetic agents. The 2 compds. were both low nanomolar inhibitors and lowered glucose in the diabetic ob/ob mouse at doses at or below 10 mg/kg/day, po.

IT **245359-81-3P 245359-83-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation, PTP1B inhibition and antihyperglycemic activity of 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes)

RN 245359-81-3 CAPLUS
CN Benzenepropanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 245359-83-5 CAPLUS
CN 2H-Isoindole-2-butanoic acid, α-[2,6-dibromo-4-(6-bromobenzo[b]naphtho[2,3-d]thien-11-yl)phenoxy]-1,3-dihydro-1,3-dioxo-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d que l20 Inventor Search
L1 STR

O 37 S 38 N 39 C M2

H 35 O 36

S 34

Cy 33



Page 1-A



^^^^^

Page 1-B



Page 2-A

31 C~~~~~C 32

Page 2-B
VAR G2=33/24
VAR G3=34/31-8 32-5
VAR G4=35/36
VAR G5=37/38/39/40
NODE ATTRIBUTES:
HCOUNT IS M2 AT 40
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3

```
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS R      AT   6
NSPEC   IS R      AT   7
NSPEC   IS R      AT   8
NSPEC   IS R      AT   9
NSPEC   IS R      AT  10
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS R      AT  14
NSPEC   IS R      AT  15
NSPEC   IS R      AT  16
NSPEC   IS R      AT  17
NSPEC   IS R      AT  18
NSPEC   IS R      AT  19
NSPEC   IS R      AT  20
NSPEC   IS R      AT  21
NSPEC   IS R      AT  22
NSPEC   IS R      AT  23
NSPEC   IS C      AT  24
NSPEC   IS C      AT  25
NSPEC   IS C      AT  26
NSPEC   IS C      AT  27
NSPEC   IS C      AT  28
NSPEC   IS C      AT  29
NSPEC   IS C      AT  30
NSPEC   IS C      AT  31
NSPEC   IS C      AT  32
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  24 25 27 29 31 32 33 34 35 36 37 38 39 40
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  40

STEREO ATTRIBUTES: NONE
L8            93 SEA FILE=REGISTRY SSS FUL L1
L10            7 SEA FILE=CAPLUS ABB=ON  PLU=ON  L8
L13           40 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("WALLACE O"/AU OR "WALLACE O
                 B"/AU OR "WALLACE OWEN"/AU OR "WALLACE OWEN B"/AU OR "WALLACE
                 OWEN BRENDAN"/AU OR "WALLACE OWEN BRENDON"/AU)
L14            2 SEA FILE=CAPLUS ABB=ON  PLU=ON  L13 AND L10
L16            2 SEA FILE=CAPLUS ABB=ON  PLU=ON  L13 AND (?ANTHRAC?)/BI
L17            1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L13 AND ANTHRAC?/OBI
L18            2 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L16 OR L17)
L19           15 SEA FILE=CAPLUS ABB=ON  PLU=ON  L13 AND ESTROGEN?/OBI (3A)
                 RECEPTOR?/OBI
L20           15 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L19 OR L18 OR L14)


=> d ibib abs l20 tot

L20  ANSWER 1 OF 15  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2006:26815  CAPLUS
DOCUMENT NUMBER:         144:163512
TITLE:                   A Selective Estrogen Receptor
                         Modulator for the Treatment of Hot Flushes
```

AUTHOR(S): **Wallace, Owen B.**; Lauwers, Kenneth S.; Dodge, Jeffrey A.; May, Scott A.; Calvin, Joel R.; Hinklin, Ronald; Bryant, Henry U.; Shetler, Pamela K.; Adrian, Mary D.; Geiser, Andrew G.; Sato, Masahiko; Burris, Thomas P.
CORPORATE SOURCE: Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA
SOURCE: Journal of Medicinal Chemistry (2006), 49(3), 843-846 CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A selective estrogen receptor modulator (SERM) for the potential treatment of hot flushes is described. (R)-(+)-7,9-difluoro-5-[4-(2-piperidin-1-ylethoxy)phenyl]-5H-6-oxachrysen-2-ol, LSN2120310, potently binds ERα and ERβ and is an antagonist in MCF-7 breast adenocarcinoma and Ishikawa uterine cancer cell lines. The compound is a potent estrogen antagonist in the rat uterus. In ovariectomized rats, the compound lowers cholesterol, maintains bone mineral d., and is efficacious in a morphine dependent rat model of hot flush efficacy.
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1055907 CAPLUS
DOCUMENT NUMBER: 143:415737
TITLE: A new selective **estrogen receptor** modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation
AUTHOR(S): Geiser, Andrew G.; Hummel, Conrad W.; Draper, Michael W.; Henck, Judith W.; Cohen, Ilene R.; Rudmann, Daniel G.; Donnelly, Kevin B.; Adrian, Mary D.; Shepherd, Timothy A.; **Wallace, Owen B.**; McCann, Denis J.; Oldham, Samuel W.; Bryant, Henry U.; Sato, Masahiko; Dodge, Jeffrey A.
CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, IN, 46285, USA
SOURCE: Endocrinology (2005), 146(10), 4524-4535 CODEN: ENDOAO; ISSN: 0013-7227
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The use of selective estrogen receptor modulators for the treatment of estrogen-dependent diseases in premenopausal women has been hindered by undesirable ovarian stimulation and associated risks of ovarian cysts. The authors have identified a selective estrogen receptor modulator compound (LY2066948) that is a strong estrogen antagonist in the uterus yet has minimal effects on the ovaries of rats. LY2066948 binds with high affinity to both estrogen receptors and has potent estrogen antagonist activity in human uterine and breast cancer cells. Oral administration of LY2066948 to immature rats blocked uterine weight gain induced by ethynyl estradiol with an ED50 of 0.07 mg/kg. Studies in mature rats demonstrated that LY2066948 decreases uterine weight by 51% after 35 d treatment, confirming potent uterine antagonist activity over several estrus cycles. This strong uterine response contrasted with the minimal effects on the ovaries: serum estradiol levels remained within the normal range, whereas histol. evaluation showed granulosa cell hyperplasia in few of the rats. Bone studies demonstrated that LY2066948 prevented ovariectomy-induced

bone loss and treatment of ovary-intact rats caused no bone loss, confirming estrogen receptor agonist skeletal effects. Collectively, these data show that LY2066948 exhibits a tissue-specific profile consistent with strong antagonist activity in the uterus, agonist activity in bone, and minimal effects in the ovaries.

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1051070 CAPLUS
DOCUMENT NUMBER: 143:359450
TITLE: A Selective **Estrogen Receptor** Modulator Designed for the Treatment of Uterine Leiomyoma with Unique Tissue Specificity for Uterus and Ovaries in Rats
AUTHOR(S): Hummel, Conrad W.; Geiser, Andrew G.; Bryant, Henry U.; Cohen, Ilene R.; Dally, Robert D.; Fong, Kin Chiu; Frank, Scott A.; Hinklin, Ronald; Jones, Scott A.; Lewis, George; McCann, Denis J.; Rudmann, Daniel G.; Shepherd, Timothy A.; Tian, Hongqi; **Wallace, Owen B.**; Wang, Minmin; Wang, Yong; Dodge, Jeffrey A.
CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company Lilly Corporate Center, Indianapolis, IN, 46285, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(22), 6772-6775
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. Compound (I, LY2066948-HCl) binds with high affinity to estrogen receptors α and β (ERα and ERβ, resp.) and is a potent uterine antagonist with minimal effects on the ovaries as determined by serum biomarkers and histol. evaluation.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:732663 CAPLUS
DOCUMENT NUMBER: 143:193907

TITLE: Preparation of 5H-6-oxa-chrysene derivatives as selective **estrogen receptor** modulators
INVENTOR(S): Dodge, Jeffrey Alan; Hopkins, Randall Bruce; **Wallace, Owen Brendan**
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073244	A1	20050811	WO 2005-US19	20050118

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-538302P P 20040122
OTHER SOURCE(S): MARPAT 143:193907
GI



I

AB The present invention relates to a selective estrogen receptor modulators, I (n = independently 0,1,2; R8 = H, SO2-alkyl, COR3; R0 = OH, CF3, C1-6 alkyl, or C1-6 alkoxy; R1 = C1-6 alkyl, C1-6 alkoxy, amine CF3, CH2CF3; R2 = H, Me; X = O or substituted amine; Y = O or S), for treating endometriosis and uterine leiomyoma.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:732630 CAPLUS
DOCUMENT NUMBER: 143:211842

TITLE: Preparation of piperidine derivatives as selective **estrogen receptor** modulators for the treatment of vasomotor symptoms

INVENTOR(S): Dally, Robert Dean; Dodge, Jeffrey Alan; Frank, Scott Alan; Hinklin, Ronald Jay; Shepherd, Timothy Alan; **Wallace, Owen Brendan**

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073204	A1	20050811	WO 2005-US20	20050118

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-538342P P 20040122
US 2004-538442P P 20040122

OTHER SOURCE(S): MARPAT 143:211842

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to selective estrogen receptor modulators (no data; shown as I; variables defined below; e.g. 1-[2-[4-[[2-(2,6-difluorophenyl)-6-methoxynaphthalen-1-yl]oxy]phenoxy]ethyl]piperidine (shown as II)) or pharmaceutical acid addition salts thereof useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause. In a morphine withdrawal, rat hot flash model, representative I were tested ≤30 mg/kg PO and caused an attenuation of tail skin temperature increase, as measured by temperature change 15 min post naloxone injection or AUC over 45 min post naloxone administration. For I: m = 0-2; n = 1-4; R is H or Me provided that if m is 1 or 2, then R must be H and that if m is 0, then R must be Me; R1 is H, SO2(n-C4-C6 alkyl) or COR2; X is O or NR3; X1 is O, CH2 or C:O; R6 is H or F or R6 combines with X1 to form III (Y is O, S, SO or NR4; e.g. 7,9-difluoro-5-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-5H-6-oxachrysen-2-ol (shown as IV)); R2 is C1-C6 alkyl, C1-C6 alkoxy, NR5R5a, phenoxy, or Ph (un)substituted with halo; R3 and R4 = H or C1-C6 alkyl; and R5 and R5a = H, C1-C6 alkyl or Ph. Although the methods of preparation are not claimed, .apprx.150 example prepns. are included. For example, II was prepared (32 %) from trifluoromethanesulfonic acid 6-methoxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester (preparation given) and

(2,6-difluorophenyl)boronic acid in DMF using potassium phosphate and tetrakis(triphenylphosphine)palladium(0).
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:729634 CAPLUS
DOCUMENT NUMBER: 143:186711
TITLE: Selective **estrogen receptor** modulators effective against endometriosis and uterine leiomyoma
INVENTOR(S): Dodge, Jeffrey Alan; Frank, Scott Alan; Hinklin, Ronald Jay; **Wallace, Owen Brendon**
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073190	A1	20050811	WO 2005-US18	20050118

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-539938P P 20040129
OTHER SOURCE(S): MARPAT 143:186711
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to selective estrogen receptor modulators (no data; shown as I-VII; variables defined below; e.g. VII (R11 = Me)) or a pharmaceutical salt thereof, useful, e.g., for treating endometriosis and uterine leiomyoma (no data). Methods of preparation are not claimed and no example prepns. are included. For I: m is 1 or 2; R and R1 are OH or SO2R11 provided that one and only one of R or R1 must be and is SO2R11; R2 and R3 are OH, OCOCMe3 or SO2R11 provided that one and only one of R2 or R3 must be and is SO2R11; R4 and R5 are OH, OCH3 or SO2R11 provided that one and only one of R4 or R5 must be and is SO2R11; R6 is H, OH, OPO(OH)2, I or SO2R11 and R10 is H, CHMe2 or SO2R11 provided that one and only one of R6 or R10 must be and is SO2R11; R7 and R8 are both Me or combine with the N to which they are attached to form a pyrrolidinyl ring; R9 is CH3 or CH2Cl; R11 is C1-C6 alkyl, C1-C6 alkoxy, NR12R13, CF3 or CH2CF3; X is CO or O; R12 is C1-C6 alkyl or phenyl; and R13 is H, C1-C6 alkyl or Ph.
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:767285 CAPLUS
DOCUMENT NUMBER: 141:410789
TITLE: Benzothiophene and naphthalene derived constrained SERMs
AUTHOR(S): **Wallace, Owen B.**; Bryant, Henry U.; Shetler, Pamela K.; Adrian, Mary D.; Geiser, Andrew G.
CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(20), 5103-5106
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:410789
AB For selective estrogen receptor modulators (SERMs), the orientation of the basic side chain relative to the SERM core has a significant impact on function. The synthesis and biol. evaluation of two series of SERMs are disclosed, where the ligand side chain is constrained to adopt a defined orientation. Compds. where the side chain is forced into the plane of the SERM core have a different profile compared to those compds. where the side chain is pseudo-orthogonal, particularly with regard to antagonism of estradiol action on an Ishikawa uterine cell line.
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:292023 CAPLUS
DOCUMENT NUMBER: 140:303419
TITLE: Preparation of dihydro-dibenzo(a)**anthracenes** as selective **estrogen receptor** modulators
INVENTOR(S): **Wallace, Owen Brendan**
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029047	A1	20040408	WO 2003-US26304	20030922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497627	AA	20040408	CA 2003-2497627	20030922
AU 2003265581	A1	20040419	AU 2003-265581	20030922

EP 1546139	A1	20050629	EP 2003-798700		20030922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003014594	A	20050809	BR 2003-14594		20030922
JP 2006508066	T2	20060309	JP 2004-539841		20030922
PRIORITY APPLN. INFO.:			US 2002-413609P	P	20020925
			WO 2003-US26304	W	20030922

OTHER SOURCE(S): MARPAT 140:303419
GI



I



II

AB Dihydro-dibenzo(a)**anthracenes** of formula I [R1 = H, OH, alkoxy, benzoyloxy, acyloxy, OSO2alkyl, etc.; R, R2, R3 = H, OH, alkoxy, benzoyloxy, acyloxy, OSO2alkyl, halo; R4 = 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n = 2-3; X = S, CH=CH; Y = O, S, NH, NMe, CH2] are prepared for pharmaceutical compns., optionally in combination with estrogen and progestin, for inhibiting a disease associated with estrogen deprivation or a disease associated with an aberrant physiol. response to endogenous estrogen. Thus, II.TFA was prepared from (2,6-dimethoxynaphthalen-1-yl)-[4-(2-piperidin-1-ylethoxy)phenyl]methanone and 3-methoxybenzylzinc chloride. II had IC50 of 2 nM against MCF-7 breast adenocarcinoma cells.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:80700 CAPLUS
DOCUMENT NUMBER: 140:128294
TITLE: Preparation of dihydrodibenzo[b,e]oxepine based selective **estrogen receptor** modulators for treatment of estrogen related diseases

INVENTOR(S): **Wallace, Owen Brendan**
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004009603	A1	20040129	WO 2003-US19554		20030711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003281632	A1	20040209	AU 2003-281632		20030711
EP 1527076	A1	20050504	EP 2003-742113		20030711
EP 1527076	B1	20051228			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005538091	T2	20051215	JP 2004-523010		20030711
AT 314375	E	20060115	AT 2003-742113		20030711
US 2005240017	A1	20051027	US 2005-521137		20050112
PRIORITY APPLN. INFO.:			US 2002-398538P	P	20020724
			WO 2003-US19554	W	20030711

OTHER SOURCE(S): MARPAT 140:128294
GI



I



II

AB Title compds. I [wherein R1 = H, OH, alkoxy, OCOPh, alkanoyloxy, or alkylsulfonyloxy; R0, R2, and R3 = independently H, OH, alkoxy, OCOPh, alkanoyloxy, alkylsulfonyloxy, or halo; R4 = piperidinyl, (un)substituted pyrrolidinyl, morpholino, dialkylamino, or piperidinyl; n = 2 or 3; X = S or CH=CH; G = O, S, SO, SO2, or NR5; R5 = H or alkyl; Y = O, S, NH, NMe, or CH2; or pharmaceutically acceptable salts thereof] were prepared as selective estrogen receptor (ER) modulators. For example, reaction of 2-methoxybenzylmagnesium chloride with (2-dimethylamino-6-methoxybenzo[b]thiophen-3-yl)[4-[2-(piperidinyl-1-yl)ethoxy]phenyl]methanone in THF , followed by deprotection using HCl/ether in CH2Cl2 gave [6-hydroxy-2-(2-hydroxybenzyl)benzo[b]thiophen-3-yl][4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone (54%). Cyclization with DIBAL in THF provided the 5,11-dihydro-6-oxa-12-thiadibenzo[a,f]azulene II (62%). In competition binding assays, the latter showed activity with Ki values of 1 nM at both of the ERα and ERβ receptors. Thus, I are useful in pharmaceutical compns., optionally in combination with estrogen and progestin, for inhibiting a disease associated with estrogen deprivation or an aberrant physiol. response to endogenous estrogen, such as bone loss, breast cancer, endometriosis, or uterine fibrosis (no data).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:80676 CAPLUS
DOCUMENT NUMBER: 140:146019
TITLE: Preparation of pentacyclic oxepines as **estrogen receptor** ligands
INVENTOR(S): Hinklin, Ronald Jay; **Wallace, Owen Brendan**
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009578	A2	20040129	WO 2003-US19561	20030718
WO 2004009578	A3	20040311		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003247589	A1	20040209	AU 2003-247589	20030718
EP 1551822	A2	20050713	EP 2003-765456	20030718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005538092	T2	20051215	JP 2004-523013	20030718
US 2005261277	A1	20051124	US 2005-521998	20050118
PRIORITY APPLN. INFO.:			US 2002-398537P P	20020724
			WO 2003-US19561 W	20030718

OTHER SOURCE(S): MARPAT 140:146019
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, OH, alkoxy, acyloxy, etc.; R0, R2-3 = H, OH, alkoxy, etc.; R4 = piperidinyl, pyrrolidinyl, etc.; n = 2-3; X = S, HC.tplbond.CH; G = O, SO0-2, amino, etc.] are prepared For instance, 2-(1,3-dioxolan-2-yl)phenylmagnesium bromide is added to (2-dimethylamino-6-methoxybenzo[b]thiophen-3-yl)[4-(2-(piperidin-1-yl)ethoxy)phenyl]methanone (THF) and the resulting acetal deprotected (THF/H2O, HCl, reflux, 30 min) and reduced/cyclized (THF, LAH) to give II. Tested I bound to ERα receptors with Ki = 0.7-300 nM. I, optionally in combination with estrogen or progestin, are useful for inhibiting a disease associated with estrogen deprivation and for inhibiting a disease associated with an aberrant physiol. response to endogenous estrogen.

L20 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:80504 CAPLUS
DOCUMENT NUMBER: 140:128285
TITLE: Preparation of (sulfonylphenylnaphthyl)-substituted piperidines as selective **estrogen receptor** modulators (SERMs) for treating endometriosis and/or uterine leiomyoma
INVENTOR(S): Dally, Robert Dean; Dodge, Jeffrey Alan; Frank, Scott Alan; Jones, Scott Alan; Shepherd, Timothy Alan; **Wallace, Owen Brendan**; Fong, Kin Chiu; Hummel, Conrad Wilson; Lewis, Geroge Sal
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009086	A1	20040129	WO 2003-IB3349	20030716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2490580	AA	20040129	CA 2003-2490580	20030716
AU 2003253129	A1	20040209	AU 2003-253129	20030716
BR 2003012675	A	20050503	BR 2003-12675	20030716
EP 1530470	A1	20050518	EP 2003-765254	20030716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1668303	A	20050914	CN 2003-817201	20030716

JP 2005538089	T2	20051215	JP 2004-522648		20030716
AU 2004216258	A1	20040910	AU 2004-216258		20040121
CA 2512663	AA	20040910	CA 2004-2512663		20040121
WO 2004075894	A1	20040910	WO 2004-US20		20040121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1601356	A1	20051207	EP 2004-703963		20040121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1753676	A	20060329	CN 2004-80005160		20040121
NO 2005000832	A	20050216	NO 2005-832		20050216
NO 2005004400	A	20050922	NO 2005-4400		20050922
PRIORITY APPLN. INFO.:			US 2002-397869P	P	20020722
			US 2003-450233P	P	20030225
			WO 2003-IB3349	W	20030716
			WO 2004-US20	W	20040121

OTHER SOURCE(S): MARPAT 140:128285

GI



I



II

AB Title compds. I [wherein m, p, and q = independently 0-2; n = 0-1; R = H or COR2; R0 = independently OH, CF3, halo, alkyl, or alkoxy; R1 and R1' = independently alkyl, alkoxy, NR3R3a, CF3, or CH2CF3; or when n and q = 0, SO2R1 may combine with the Ph ring to form a heterocycle; R2 = alkyl,

alkoxy, NR4R4, PhO, or (halo)phenyl; R3 = alkyl or Ph; R3a and R4 = independently H, alkyl, or Ph; X = O, CH2, or CO; X1 = O or NR5; R5 = H or alkyl; R8 = H or Me; with the provisos that if p = 1 or 2, then R8 = H and if p = 0, R8 = Me; Y = S, CH2CH2, or CH=CH; and pharmaceutical acid addition salts thereof] were prepared as selective estrogen receptor modulators (no data). For example, coupling of 4-(methanesulfonyl)phenylboronic acid with trifluoromethanesulfonic acid 6-methoxy-1-[4-[2-(piperidin-1-yl)ethoxy]phenoxy]naphthalen-2-yl ester (preparation given) in the presence of CsF, Pd(OAc)2, and tricyclohexylphosphine in MeCN, followed by addition of MeOH, provided II (R = OMe) in 18% yield. Conversion of the piperidine derivative to its HCl salt (96%), demethylation using BBr3 in CH2Cl2 to give the alc. (85%), and recrystn. and treatment with 2M HCl in di-Et ether afforded II•HCl (R = OH) in 95% yield. In the antagonist mode of the Ishikawa cell proliferation assay, the latter blocked 70% of the estradiol-stimulated growth of human endometrial tumor cells. In addition, II•HCl (R = OH) inhibited estrogen-induced response when administered at 1.0 mg/kg in a 3-day rat uterus antagonist assay but did not significantly elevate circulating estradiol or LH levels in a 10-day rat hormone (ovarian stimulation) screen. Thus, I, and their pharmaceutical compns. are useful for treating endometriosis and/or uterine leiomyoma/leiomyomata.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:816645 CAPLUS
DOCUMENT NUMBER: 140:156455
TITLE: **Estrogen receptor** modulators: Relationships of ligand structure, receptor affinity and functional activity
AUTHOR(S): **Wallace, Owen B.**; Richardson, Timothy I.; Dodge, Jeffrey A.
CORPORATE SOURCE: Lilly Research Laboratories, Indianapolis, IN, 46285, USA
SOURCE: Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates) (2003), 3(14), 1663-1680
CODEN: CTMCCL; ISSN: 1568-0266
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. The estrogen receptor is a regulator of a wide range of physiol. functions, including the female reproductive system, in addition to bone, cardiovascular and CNS function. ER ligands have been approved for the treatment of menopausal symptoms, breast cancer and osteoporosis, however the search continues for new modulators of ER function with improved properties. Progress in medicinal chemical programs has resulted in the identification of structurally diverse mols. with unique biol. properties. Recent advances in the design and synthesis of these non-steroidal and steroidal estrogen receptor ligands is reviewed. The relationship between the structural features of the ligand and receptor function is also discussed.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:363826 CAPLUS
DOCUMENT NUMBER: 139:159600
TITLE: Tetrahydroquinoline-based selective **estrogen receptor** modulators (SERMs)

AUTHOR(S): **Wallace, Owen B.**; Lauwers, Kenneth S.; Jones, Scott A.; Dodge, Jeffrey A.
CORPORATE SOURCE: Lilly Research Laboratories, Discovery Chemistry Research and Technologies, Eli Lilly and Company, Indianapolis, IN, 46285, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(11), 1907-1910
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new series of estrogen receptor ligands based on a 6-hydroxy-tetrahydroquinoline scaffold is described, in addition to their binding affinity and functional activity in MCF-7 cells. Several 1,2-disubstituted tetrahydroquinolines bearing a basic side chain were shown to be high affinity ligands and antagonists in the MCF-7 proliferation assay. Compds. lacking the basic side chain were agonists in the MCF-7 assay.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:906161 CAPLUS
DOCUMENT NUMBER: 137:384759
TITLE: Preparation of tetrahydroquinolines as selective **estrogen receptor** modulators.
INVENTOR(S): **Wallace, Owen Brendan**
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002094788	A1	20021128	WO 2002-US11878		20020509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1395563	A1	20040310	EP 2002-746308		20020509
EP 1395563	B1	20060329			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004531562	T2	20041014	JP 2002-591461		20020509
AT 321754	E	20060415	AT 2002-746308		20020509
US 2004215018	A1	20041028	US 2003-475593		20031022
PRIORITY APPLN. INFO.:			US 2001-292704P	P	20010522
			WO 2002-US11878	W	20020509

OTHER SOURCE(S): MARPAT 137:384759
GI



I

AB Title compds. (I; R1 = H, OH, alkoxy, PhO2C, alkoxycarbonyl, alkylsulfonyloxy; R2, R3 = H, OH, alkoxy, PhO2C, alkoxycarbonyl, alkylsulfonyloxy, halo; R4 = piperidinyl, pyrrolidinyl, methylpyrrolidinyl, dimethylpyrrolidinyl, morpholino, Me2N, Et2N, (Me2CH)2N, azepinyl; n = 1-3; X = CO, CH2; Y = O, S, NH, NMe, CH2), were prepared Thus, 6-methoxy-2-(4-methoxyphenyl)-1,2,3,4-tetrahydroquinoline (preparation given), 4-(2-piperidin-1-ylethoxy)benzoyl chloride hydrochloride, and Et3N were stirred in CH2Cl2 to give [6-methoxy-2-(4-methoxyphenyl)-1,2,3,4-tetrahydroquinolin-1-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone. Tested I bound to ERα receptors with Ki = 0.6-87.8 μM. I, optionally in combination with estrogen or progestin, are useful for inhibiting a disease associated with estrogen deprivation and for inhibiting a disease associated with an aberrant physiol. response to endogenous estrogen.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:905861 CAPLUS
DOCUMENT NUMBER: 137:380058
TITLE: Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
INVENTOR(S): **Wallace, Owen Brendan**
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094268	A1	20021128	WO 2002-US11879	20020509

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

```
     CA 2444787           AA    20021128    CA 2002-2444787        20020509
     EP 1401446           A1    20040331    EP 2002-746309         20020509
     EP 1401446           B1    20050209
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004531559        T2    20041014    JP 2002-590985         20020509
     AT 288755            E     20050215    AT 2002-746309         20020509
     PT 1401446           T     20050531    PT 2002-746309         20020509
     ES 2236536           T3    20050716    ES 2002-2746309        20020509
     US 2004132770        A1    20040708    US 2003-475867         20031022
     US 6962928           B2    20051108
PRIORITY APPLN. INFO.:                      US 2001-292576P     P  20010522
                                            WO 2002-US11879     W  20020509
OTHER SOURCE(S):         MARPAT 137:380058
AB   The current invention provides methods for inhibiting a disease associated
     with estrogen deprivation and for inhibiting disease associated with an
     aberrant physiol. response to endogenous estrogen comprising administering
     2-substituted 1,2,3,4-tetrahydroquinolin-6-ols and derivs. thereof.
REFERENCE COUNT:         4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> file beils
FILE 'BEILSTEIN' ENTERED AT 15:27:19 ON 24 MAY 2006
COPYRIGHT (c) 2006 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON MARCH 15, 2006

FILE COVERS 1771 TO 2006.
*** FILE CONTAINS  9,516,393 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
   separate documents and can not be searched together in one query.
   Reaction data for BEILSTEIN compounds may be displayed
   immediately with the display codes PRE (preparations) and REA
   (reactions).  A substance answer set retrieved after the search
   for a chemical name, a compounds with available reaction
   information by combining with PRE/FA, REA/FA or more generally
   with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
   between a BEILSTEIN compound and belonging reactions. For mo
   detailed reaction searches BRNs can be searched as reaction
   partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE  <<<

**********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.                 *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE    *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE           *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                         *
* FOR PRICE INFORMATION SEE HELP COST                                 *
**********************************************************************
    NEW
* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE
  SEARCHED, SELECTED AND TRANSFERRED.
* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES,
  ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A
  COMPOUND AT A GLANCE.
```

=> d que l26
L1 STR

O 37 S 38 N 39 C M2

H 35 O 36

S 34

Cy 33



Page 1-A



^ ^ ^ ^ ^

Page 1-B



Page 2-A

31 C C 32

Page 2-B
VAR G2=33/24
VAR G3=34/31-8 32-5
VAR G4=35/36
VAR G5=37/38/39/40
NODE ATTRIBUTES:

HCOUNT	IS M2	AT	40
NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS R	AT	11
NSPEC	IS R	AT	12
NSPEC	IS R	AT	13
NSPEC	IS R	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS R	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21
NSPEC	IS R	AT	22

```
NSPEC   IS R      AT  23
NSPEC   IS C      AT  24
NSPEC   IS C      AT  25
NSPEC   IS C      AT  26
NSPEC   IS C      AT  27
NSPEC   IS C      AT  28
NSPEC   IS C      AT  29
NSPEC   IS C      AT  30
NSPEC   IS C      AT  31
NSPEC   IS C      AT  32
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  24 25 27 29 31 32 33 34 35 36 37 38 39 40
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  40

STEREO ATTRIBUTES: NONE
L8            93 SEA FILE=REGISTRY SSS FUL L1
L22              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L24           12 SEA FILE=BEILSTEIN SSS FUL L22
L25           12 SEA FILE=BEILSTEIN ABB=ON  PLU=ON  L24 NOT L8
L26           12 SEA FILE=BEILSTEIN ABB=ON  PLU=ON  L25 AND BABSAN/FA


=> d ide allref l26 1


L26  ANSWER 1 OF 12 BEILSTEIN COPYRIGHT 2006 BEILSTEIN MDL on STN

     Beilstein Records (BRN):        9884696
     Chemical Name (CN):             12-<4-(2-piperidin-1-yl-ethoxy)-phenyl>-
                                     7,12-dihydro-benzo<a>anthracene-3,9-diol
     Autonom Name (AUN):             12-<4-(2-piperidin-1-yl-ethoxy)-phenyl>-
                                     7,12-dihydro-benzo<a>anthracene-3,9-diol
     Molec. Formula (MF):            C31 H31 N O3
     Molecular Weight (MW):          465.59
     Lawson Number (LN):             24081, 6623, 3122
     File Segment (FS):              Stereo compound
     Compound Type (CTYPE):          heterocyclic
     Constitution ID (CONSID):       8321847
     Tautomer ID (TAUTID):           9259912
     Entry Date (DED):               2005/04/22
     Update Date (DUPD):             2005/04/22
```



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	3
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
DED	Entry Date	1
DUPD	Update Date	1
PHARM	Pharmacological Data	5

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

All References:
ALLREF

1. Wallace, Owen B.; Bryant, Henry U.; Shetler, Pamela K.; Adrian, Mary D.; Geiser, Andrew G., Bioorg. Med. Chem. Lett., CODEN: BMCLE8, 14(20), <2004>, 5103 - 5106; BABS-6471965

```
=> file marpat
FILE 'MARPAT' ENTERED AT 15:27:47 ON 24 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 144 ISS 21 (20060519/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987
```

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US	2006062725	23 MAR 2006
DE	102004043368	09 MAR 2006
EP	1632495	08 MAR 2006
JP	2006066839	09 MAR 2006
WO	2006042453	27 APR 2006
GB	2416167	18 JAN 2006
FR	2875804	31 MAR 2006
RU	2270725	27 FEB 2006
CA	2514373	19 FEB 2006

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

=> d que l34
L1 STR

O 37 S 38 N 39 C M2

H 35 O 36

S 34

Cy 33



Page 1-A



^^^^^

Page 1-B



Page 2-A

31 C C 32

Page 2-B
VAR G2=33/24
VAR G3=34/31-8 32-5
VAR G4=35/36
VAR G5=37/38/39/40
NODE ATTRIBUTES:
HCOUNT IS M2 AT 40
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3

```
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS R      AT   6
NSPEC   IS R      AT   7
NSPEC   IS R      AT   8
NSPEC   IS R      AT   9
NSPEC   IS R      AT  10
NSPEC   IS R      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS R      AT  14
NSPEC   IS R      AT  15
NSPEC   IS R      AT  16
NSPEC   IS R      AT  17
NSPEC   IS R      AT  18
NSPEC   IS R      AT  19
NSPEC   IS R      AT  20
NSPEC   IS R      AT  21
NSPEC   IS R      AT  22
NSPEC   IS R      AT  23
NSPEC   IS C      AT  24
NSPEC   IS C      AT  25
NSPEC   IS C      AT  26
NSPEC   IS C      AT  27
NSPEC   IS C      AT  28
NSPEC   IS C      AT  29
NSPEC   IS C      AT  30
NSPEC   IS C      AT  31
NSPEC   IS C      AT  32
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  24 25 27 29 31 32 33 34 35 36 37 38 39 40
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  40

STEREO ATTRIBUTES: NONE
L8            93 SEA FILE=REGISTRY SSS FUL L1
L10            7 SEA FILE=CAPLUS ABB=ON  PLU=ON  L8
L22              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L32            5 SEA FILE=MARPAT SSS FUL L22
L33            4 SEA FILE=MARPAT ABB=ON  PLU=ON  L32/COM
L34            1 SEA FILE=MARPAT ABB=ON  PLU=ON  L33 NOT L10


=> d ibib abs qhit l34 tot

L34  ANSWER 1 OF 1  MARPAT  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         126:124543  MARPAT
TITLE:                    Organic electroluminescent device
INVENTOR(S):              Nakatani, Kenji; Inoe, Tetsuji
PATENT ASSIGNEE(S):       Tdk Electronics Co Ltd, Japan
SOURCE:                   Jpn. Kokai Tokkyo Koho, 25 pp.
                          CODEN: JKXXAF
```

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08311442	A2	19961126	JP 1995-142507	19950517
JP 3712760	B2	20051102		
US 6203933	B1	20010320	US 1996-648766	19960516
JP 2005327740	A2	20051124	JP 2005-202075	20050711

PRIORITY APPLN. INFO.: JP 1995-142507 19950517

AB The invention relates to an organic electroluminescent device having sufficient intensity in the yellow and red regions, wherein the light emitting layer contains the compound represented by (Ar)m-L [Ar = aromatic; m = integer 2-6; L = m-valent polycyclic aromatic residue with 3-10 rings; if L is di- or trivalent anthracene derivative, then ≥1 Ar is alkynylarene; if L is tetravalent 5,6,11,12-Ar substituted naphthacene derivative, then four Ar's may not all be Ph].

MSTR 1

G1—G2

G1 = 3 / 326

G3—G7
3



G2 = 956



G3 = alkynylene
G4 = aryl (opt. substd.)
G15 = 385

G3—G7
385

G16 = 391

G3—G4
391

Patent location: claim 1
Note: substitution is restricted